JSJeffrey T. Schouten

Jeffrey T. Schouten

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jeffrey T. Schouten has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Anne Kmack

    Science and Technology Research Foundation, Amherst

    2 shared publications
  • Daniel R. Kuritzkes

    Section of Retroviral Therapeutics, Brigham and Women's Hospital, Boston, Massachusetts

    2 shared publications
  • Roy M. Gulick

    Division of Infectious Diseases, Weill Medical College of Cornell University, New York, New York

    2 shared publications
  • Amy Krambrink

    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts

    1 shared publication
  • Ann C. Collier

    University of Washington, Seattle; Seattle, WA

    1 shared publication
  • Cecilia Shikuma

    Hawaii AIDS Clinical Research Program, Department of Medicine, University of Hawaii School of Medicine, Honolulu

    1 shared publication

Latest Publications

  • Open Access

    Reply to Gelinck and Burger

    by Jeffrey T. Schouten, Anne Kmack, Daniel R. Kuritzkes, Roy M. Gulick

    To the Editor—Gelinck and Burger [1] note that nevirapine (NVP) and efavirenz (EFV) are both substrates and inducers of the CYP3A4 enzyme system and question the need for a 2-week lead-in with NVP when switching from EFV. At the time that the AIDS Clinical Trials Group A5095 study performed enrollment (March 2001–November 2002), there were few data on the proper dosing strategy to use when substituting NVP for EFV. We took a conservative approach in dosing NVP at the once-daily 200-mg dose for 14 days, as recommended by the NVP package insert, when switching patients from EFV to NVP [2]. However, it may be possible to begin with the twice-daily dose of NVP when switching patients from EFV to NVP. A subsequent comparison of immediate twice-daily NVP dosing versus a 2-week period of once-daily dosing in 12 patients supported twice-daily dosing of NVP after EFV exposure [3]. It was initially observed in 2001 [4] and was confirmed in 2005 [5] that NVP, if dosed together with EFV, increases EFV clearance. However, plasma EFV clearance in subjects is variable and prolonged. Subjects with CYP2B6 GG genotype at position 516 were predicted to yield EFV protein-adjusted IC95 at a concentration higher than 46.7 ng/mL for a median of 5.8 days; subjects with CYP2B6 GT genotype at position 516 were predicted to yield EFV protein-adjusted IC95 at a concentration higher than 46.7 ng/mL for a median of 7.0 days; and subjects with CYP2B6 TT genotypes at position 516 were predicted to yield EFV protein-adjusted IC95 at a concentration higher than 46.7 ng/mL for a median of 14 days [6]. In a cohort of 394 patients who switched from EFV to twice-daily NVP because of a change in the drug formulary, adverse event rates were similar to those in patients who initiated NVP at 200 mg once daily for the first 2 weeks [7].

  • Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095

    by Jeffrey T. Schouten, Amy Krambrink, Heather J. Ribaudo, Anne Kmack, Nancy Webb, Cecilia Shikuma, Daniel R. Kuritzkes, Roy M. Gulick

    In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine. Most adverse events resolved; 15 participants ultimately discontinued nevirapine therapy. Grade 3/4 hepatotoxicity was observed in 14% of individuals who substituted nevirapine, compared with 6% who continued efavirenz therapy. Substitution of nevirapine because of efavirenz toxicity was generally safe and efficacious. Clinical trials registration. NCT00013520 .


  • Open Access

    A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people

    by Jeffrey T Schouten, David W Lockhart, Thomas S Rees, Ann C Collier, Christina M Marra

    Background: While hearing loss in HIV-infected people after beginning nucleoside reverse transcriptase inhibitors (NRTIs) has been reported, there have been no prospective studies that measured hearing changes longitudinally in treatment-naïve HIV-infected subjects following initiation of regimens containing NRTIs. The goal of this study was to conduct a prospective assessment of the contribution of zidovudine (ZDV) and didanosine (ddI) to hearing lossMethods/design: A prospective observational pilot study to determine whether ZDV or ddI, alone or in combination, are associated with sensorineural hearing loss in HIV-infected persons. Changes in hearing levels at all frequencies and in low and high frequency pure tone averages were measured at baseline, 16, and 32 weeks after initiating antiretroviral therapy.Discussion: Treatment with ZDV and ddI did not result in loss of hearing, even after taking into account noise exposure, immune status and age. The results of this prospective pilot study do not support the notion that treatment with nucleoside antiretrovirals damages hearing.